News Sentiment

TRAW sentiment intelligence

Traws Pharma Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 49 Balanced news tone 53 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 0.67 Week of 17 Jul 2026
Weighted tone 49/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

83/100 classification confidence.

Company focus 44

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend inactive

-11.7% over one week, -21.1% over four weeks, trend inactive, and below fair value.

Latest direct headline Negative

Traws Pharma (TRAW) Registration filing Summary

Market Reaction

Price moving ahead of tone

60/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 83/100 classification
One-week reaction -11.7% Price reacting lower
Trend fit Trend inactive -21.1% over four weeks
Fair value -91.7% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 4
Neutral 42
Negative 7

Relevance

Why the article matched

Direct first
Direct company coverage 44
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 18
TradingView 7
Market source 6
GlobeNewswire 4
Quartr 2
Investing.com Nigeria 2
MT Newswires 2
simplywall.st 2

Event Lens

What the news is about

Classified themes
Market update 33
Earnings 13
Regulatory and legal 3
Balance sheet 2
Analyst action 1
Guidance 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 53
Quartr Direct company coverage

Traws Pharma (TRAW) Registration filing Summary

Traws Pharma (TRAW) has filed a registration summary outlining its business model as a clinical-stage biopharmaceutical company focused on antiviral and oncology therapies. The company faces financial challenges, including recurring losses and liquidity concerns, but is seeking t

Tone
Negative 34/100
Event
Balance sheet
Published
18 Jul 2026 21:40
Source
Quartr
Stock Titan Direct company coverage

Traws Pharma (TRAW) grants 97,000 stock options to science chief

Traws Pharma, Inc. (TRAW) has granted 97,000 stock options to its Chief Science Officer of Virology, Charles David Pauza. The options, priced at $0.68 per share, are part of a compensation award and will vest 100% on July 9, 2027, with an expiration date of July 9, 2036. This tra

Tone
Neutral 50/100
Event
Market update
Published
16 Jul 2026 17:10
Source
Stock Titan
Stock Titan Direct company coverage

Traws Pharma (TRAW) awards 14,150 stock options to director Cautreels

Traws Pharma (TRAW) has granted 14,150 stock options to its director Werner Cautreels. These options, awarded on July 9, 2026, have an exercise price of $0.68 per share, will vest 100% after one year, and are set to expire on July 9, 2036. This transaction was reported on an SEC

Tone
Neutral 50/100
Event
Market update
Published
16 Jul 2026 01:41
Source
Stock Titan
Stock Titan Direct company coverage

Traws Pharma (TRAW) grants CFO Parker Nolan 90,000 stock options

Traws Pharma (TRAW) has granted its Chief Financial Officer, Parker Charles Nolan, 90,000 stock options with an exercise price of $0.68 per share. These options will vest completely on July 9, 2027, which is the first anniversary of the grant date, and will expire on July 9, 2036

Tone
Neutral 50/100
Event
Market update
Published
16 Jul 2026 00:10
Source
Stock Titan
Investing.com Nigeria Direct company coverage

Form 4 Traws Pharma Inc For: 15 July By Investing.com

This article from Investing.com reports on a Form 4 filing for Traws Pharma Inc on July 15th, noting that the company's stock symbol is TRAW and its price increased by 1.47%. The content primarily consists of market data, news headlines, and navigational links, typical of a finan

Tone
Neutral 50/100
Event
Market update
Published
15 Jul 2026 21:38
Source
Investing.com Nigeria
Stock Titan Direct company coverage

Traws Pharma (TRAW) awards COO 93,000 stock options at $0.68 strike

Traws Pharma (TRAW) has granted its Chief Operating Officer, Nikolay Savchuk, 93,000 stock options at an exercise price of $0.68 per share. These options, which expire on July 9, 2036, will vest completely on the first anniversary of the grant date, July 9, 2026. This transaction

Tone
Neutral 50/100
Event
Market update
Published
15 Jul 2026 20:45
Source
Stock Titan
Stock Titan Direct company coverage

Traws Pharma (TRAW) awards 14,150 stock options to director Jack E. Stover

Traws Pharma, Inc. (TRAW) has granted 14,150 stock options to its director, Jack E. Stover, on July 9, 2026. The options have an exercise price of $0.68 per share and were awarded as compensation under the company's 2021 Incentive Compensation Plan, vesting 100% after one year an

Tone
Neutral 50/100
Event
Market update
Published
15 Jul 2026 02:14
Source
Stock Titan
Investing.com Nigeria Direct company coverage

Form 4 Traws Pharma Inc For: 14 July By Investing.com

This article from Investing.com is a brief announcement regarding a Form 4 filing for Traws Pharma Inc. on July 14. It indicates the stock symbol TRAW and its performance, currently up 2.92%. The piece appears to be a basic notification that such a financial document has been mad

Tone
Positive 60/100
Event
Market update
Published
15 Jul 2026 01:14
Source
Investing.com Nigeria
Stock Titan Direct company coverage

Traws Pharma (TRAW) awards 274,000 stock options to CEO Dukes

Traws Pharma, Inc. (TRAW) has granted its CEO, Iain D. Dukes, stock options for 274,000 common shares with an exercise price of $0.68 per share. These options, awarded under the company's 2021 Incentive Compensation Plan, will vest 100% on July 9, 2027, and expire on July 9, 2036

Tone
Neutral 50/100
Event
Market update
Published
15 Jul 2026 00:39
Source
Stock Titan
Stock Titan Direct company coverage

Traws Pharma (TRAW) awards 14,150 stock options to board director

Traws Pharma's director, Mary Teresa Shoemaker, was granted 14,150 stock options at an exercise price of $0.68 per share on July 9, 2026. These options, granted under the 2021 Incentive Compensation Plan, will vest 100% on their first anniversary and expire on July 9, 2036. This

Tone
Neutral 50/100
Event
Market update
Published
15 Jul 2026 00:14
Source
Stock Titan
Stock Titan Direct company coverage

Traws Pharma (TRAW) awards CMO 84,000 stock options at $0.68

Traws Pharma, Inc. (TRAW) granted its Chief Medical Officer, Robert Redfield, 84,000 stock options with an exercise price of $0.68 per share. The options were awarded under the company’s 2021 Incentive Compensation Plan, have a transaction price of $0.00, and fully vest on the fi

Tone
Neutral 50/100
Event
Market update
Published
15 Jul 2026 00:14
Source
Stock Titan
The Globe and Mail Direct company coverage

Traws Pharma Announces New At-The-Market Offering Program

Traws Pharma announced a new At-The-Market Offering Agreement with Citizens JMP Securities, LLC, allowing them to sell up to $50 million of common stock. This program provides the company with flexible capital access to support ongoing operations and development activities. Despi

Tone
Negative 35/100
Event
Market update
Published
12 Jul 2026 11:14
Source
The Globe and Mail
Investing.com South Africa Direct company coverage

Form 424B5 Traws Pharma Inc For: 10 July By Investing.com

Investing.com published a Form 424B5 filing for Traws Pharma Inc on July 10th. The article briefly mentions Traws Pharma Inc (TRAW) with a reported gain of 12.59%. It provides no further details on the filing or the company's financials but is part of a larger financial news port

Tone
Positive 59/100
Event
Market update
Published
10 Jul 2026 22:08
Source
Investing.com South Africa
Stock Titan Direct company coverage

Traws Pharma (NASDAQ: TRAW) details $5,575,709 baby shelf ATM stock capacity

Traws Pharma (NASDAQ: TRAW) announced details of an at-the-market (ATM) equity offering program through an 8-K filing. The company can sell up to $5,575,709 in common stock under a new prospectus supplement, which reflects its current "baby shelf" limitation, through Citizens JMP

Tone
Neutral 50/100
Event
Market update
Published
10 Jul 2026 20:09
Source
Stock Titan
Stock Titan Direct company coverage

Traws Pharma, Inc. SEC Filing

This article reports on Traws Pharma, Inc.'s SEC filing, specifically a Notice of Effectiveness for an S-3 form, which became effective on July 9, 2026. The filing indicates a "Neutral" impact and sentiment. The company, trading under NASDAQ: TRAW, has a market cap of $10.28 mill

Tone
Neutral 50/100
Event
Market update
Published
10 Jul 2026 10:09
Source
Stock Titan
Minichart Direct company coverage

Traws Pharma, Inc. Files 8-K: Amendment to 2021 Incentive Compensation Plan and Company Details Disclosed

Traws Pharma, Inc. (NASDAQ: TRAW) announced the results of its 2026 Annual Meeting of Stockholders, where shareholders approved an amendment to increase the common stock available for its 2021 Incentive Compensation Plan by 2,000,000 shares and ratified KPMG LLP as the independen

Tone
Neutral 50/100
Event
Earnings
Published
10 Jul 2026 01:40
Source
Minichart
Stock Titan Direct company coverage

Traws Pharma (NASDAQ: TRAW) shareholders approve equity plan expansion and warrant share issuances

Traws Pharma shareholders approved the expansion of its 2021 Incentive Compensation Plan by 2,000,000 shares and authorized the issuance of common shares upon the exercise of Series B and Series C warrants from an April 2026 Securities Purchase Agreement. The annual meeting also

Tone
Neutral 50/100
Event
Market update
Published
09 Jul 2026 19:50
Source
Stock Titan
Quartr Direct company coverage

Traws Pharma (TRAW) AGM 2026 Summary

This article summarizes the Traws Pharma (TRAW) 2026 Annual General Meeting (AGM) held virtually on July 8, 2026. Key items included the election of seven directors, approval of an amendment to the 2021 Incentive Compensation Plan, ratification of KPMG LLP as auditor, and authori

Tone
Neutral 50/100
Event
Regulatory and legal
Published
08 Jul 2026 19:09
Source
Quartr
Finviz Direct company coverage

TRAW - Traws Pharma Inc Options

This article provides a detailed financial overview of Traws Pharma Inc (TRAW) options. It includes various real-time financial metrics such as market capitalization, income, sales, insider and institutional ownership, profitability ratios, and stock performance data across diffe

Tone
Negative 31/100
Event
Market update
Published
02 Jul 2026 20:10
Source
Finviz
scanx.trade Direct company coverage

Traws Pharma files prospectus for $139.2M mixed shelf offering

Traws Pharma has filed a prospectus for a mixed shelf offering of up to $139.2 million, allowing it to sell various securities including common stock, preferred stock, debt securities, warrants, and units. The specifics of each offering will be detailed in a prospectus supplement

Tone
Negative 38/100
Event
Balance sheet
Published
01 Jul 2026 22:10
Source
scanx.trade
Stock Titan Direct company coverage

Traws Pharma (TRAW) renews shelf for $139.2M unsold securities

Traws Pharma, Inc. (TRAW) has filed a Form S-3 registration statement to renew its shelf for unsold securities, totaling up to $139.2 million. This filing replaces a prior registration statement and allows the company to offer various securities, including common stock, preferred

Tone
Negative 39/100
Event
Market update
Published
01 Jul 2026 20:10
Source
Stock Titan
TradingView Direct company coverage

Price to book forward of Traws Pharma, Inc. – NASDAQ:TRAW

This article displays the "Price to book forward" financial metric for Traws Pharma, Inc. (NASDAQ: TRAW) on TradingView. It presents a value and change percentage for a specified period, noting that the data is made and presented by humans.

Tone
Neutral 50/100
Event
Market update
Published
29 Jun 2026 05:11
Source
TradingView
TradingView Direct company coverage

Price to sales forward of Traws Pharma, Inc. – NASDAQ:TRAW

The article focuses on the "Price to sales forward" financial metric for Traws Pharma, Inc. (NASDAQ: TRAW), providing a snapshot of its current value and historical changes. It appears to be a financial data snippet from a larger platform rather than a detailed analysis. The cont

Tone
Neutral 50/100
Event
Market update
Published
28 Jun 2026 23:41
Source
TradingView
TradingView Direct company coverage

TRAW Forecast — Price Target — Prediction for 2027

This article provides a forecast and price target for Traws Pharma, Inc. (TRAW) stock, based on analyst opinions. It includes current stock performance, historical highs and lows, volatility metrics, market capitalization, and upcoming earnings report dates. The article also cove

Tone
Negative 38/100
Event
Analyst action
Published
27 Jun 2026 05:39
Source
TradingView
GlobeNewswire Direct company coverage

Traws Pharma Provides Updated Guidance on Influenza Prophylaxis Program

Traws Pharma announced it is developing an updated toxicology data package for its influenza prophylaxis program, tivoxavir marboxil (TXM), in response to requirements from the UK's MHRA. This resubmission, expected in Q3 2026, aims to enable a Phase 2a human influenza Challenge

Tone
Positive 66/100
Event
Guidance
Published
26 Jun 2026 19:40
Source
GlobeNewswire